Articles tagged "Induction therapy"

2021 American Transplant Congress
The Impact of Fixed-Dose Alemtuzumab in Renal Transplant Recipients According to Weight
S. Mandala¹, N. Khodieva², A. Bigness¹, S. Mohamed², H. Mohammed¹, K. Robichaux², A. Brueckner³, R. Baliga⁴, J. Buggs⁵, A. Kumar¹, L. Bowman³
¹Morsani College of Medicine, University of South Florida, Tampa, FL, ²Honors College, University of South Florida, Tampa, FL, ³Transplant Pharmacy, Tampa General Hospital, Tampa, FL, ⁴Nephrology, Florida Kidney Physicians, Tampa, FL, ⁵Transplant Surgery, Tampa General Hospital, Tampa, FL
*Purpose: Alemtuzumab, a potent anti-CD52 monoclonal antibody is used for induction immunosuppression post-renal transplantation as a fixed 30mg dose regardless of the patient’s weight. The…
2021 American Transplant Congress
Preemptive Second Kidney Transplant Outcomes by Induction Type in the United States
S. Riad¹, G. Larrieux², S. Jackson³, R. Kandaswamy²
¹Medicine, University of Minnesota, Minneapolis, MN, ²Surgery, University of Minnesota, Minneapolis, MN, ³Complex Care Analytics, M-Health Fairview, Minneapolis, MN
*Purpose: Failed kidney allograft is the fourth leading indication for kidney transplantation. A significant portion of second kidney transplant recipients undergo preemptive transplantation while on…
2021 American Transplant Congress
Outcomes of Second Kidney Transplant After Return to Dialysis by Induction Type in the United States
S. Riad¹, T. Shaker¹, S. Jackson², R. Kandaswamy³
¹Medicine, University of Minnesota, Minneapolis, MN, ²Complex Care Analytics, M-Health Fairview, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN
*Purpose: A failed kidney allograft is the 4th leading indication for kidney transplantation. We examined the association of induction use in 2nd kidney transplant recipients…
2021 American Transplant Congress
Outcomes in Standard vs. Extended Use of Thymoglobulin as Induction Therapy in Kidney Transplant Recipients
N. M. Sifontis¹, A. Coleman¹, D. Tang¹, K. Lau², S. Karhadkar², A. DiCarlo², A. Diamond²
¹Temple University School of Pharmacy, Philadelphia, PA, ²Temple University Health System, Philadelphia, PA
*Purpose: Thymoglobulin induction along with modern maintenance immunosuppression has been found to have a significant reduction in acute rejection in kidney transplantation. The recommended duration…
2021 American Transplant Congress
Sirolimus (srl) versus Everolimus (evr) versus Mycophenolate (mpa) in Kidney Transplant Recipients Receiving Anti-thymocyte Globulin Induction (r-atg), Tacrolimus (tac), and Prednisone
H. Tedesco Silva Junior, C. Felipe, L. Viana, M. Cristelli, N. Tenorio, V. Lima, V. Azevedo, K. Ficher, J. Rezende, R. Foresto, M. Nakamura, Y. Dreige, J. Taddeo, C. Zito, J. Medina
Hospital do Rim, Universidade Federal de São Paulo, São Paulo, Brazil
*Purpose: The aim of this study is to compare the efficacy and safety of SRL versus EVR versus MPA in kidney transplant recipients.*Methods: This is…
2021 American Transplant Congress
Alemtuzumab vs Antithymocyte Globulin Induction in Hepatitis C Viremic Donors to Hepatis C Negative Kidney Transplant Recipients
K. Walter, L. Mincemoyer, J. Giang, J. Suero, N. Shah, K. Szempruch
University of North Carolina Medical Center, Chapel Hill, NC
*Purpose: The optimal induction agent for kidney transplantation of hepatitis C virus nucleic acid test positive donors to negative recipients (HCV NAT D+/R-) is unknown.…
2021 American Transplant Congress
Induction in Pancreas Transplantation: T-Cell Depletion vs. Il-2 Receptor Blockade
F. Aziz, S. Parajuli, D. Kaufman, J. Odorico, D. Mandelbrot
University of Wisconsin, Madison, WI
*Purpose: There are limited data comparing outcomes with different induction agents in pancreas transplantation. In this study, we compare T-cell depletion to IL-2 receptor (IL2R)…
2021 American Transplant Congress
Dual-Agent Induction Therapy for Pancreas Transplantation: A Single-center Experience
E. C. Liu¹, J. H. Lee¹, R. Craig-Schapiro², M. Aull², S. Sultan²
¹Pharmacy, NewYork-Presbyterian Weill Cornell Medical Center, New York, NY, ²Kidney/Pancreas Transplant Surgery, NewYork-Presbyterian Weill Cornell Medical Center, New York, NY
*Purpose: The optimal induction strategy in pancreas transplantation has not been elucidated. Available evidence supports use of both basiliximab and lymphocyte depleting agents. Rabbit anti-thymocyte…
2021 American Transplant Congress
Induction Immunosuppression Efficacy in Pancreas and Kidney Transplantation in the SARS-CoV-2 Era
H. Sarumi, K. Vassar, S. Jackson, T. Pruett, R. Kandaswamy
University of Minnesota, Minneapolis, MN
*Purpose: Lymphocyte depleting induction is associated with increased risk of infection. Our institution adopted a stratified induction protocol with the intent to decrease risk for…
2020 American Transplant Congress
Evaluation of Infectious and Malignant Complications in Elderly Renal Transplant Recipients Receiving Alemtuzumab Compared to Basiliximab
K. Lang¹, J. Shulte¹, K. Cunningham¹, C. D'Agostino¹, M. Kapugi¹, C. Kane¹, A. Novak¹, J. Leventhal²
¹Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ²Division of Transplant Surgery, Northwestern Memorial Hospital, Chicago, IL
*Purpose: The choice of induction immunosuppression can affect several outcomes after kidney transplant (KTx), especially for elderly recipients. For this population, there is limited data…